Form 4: CalciMedica Chief Business Officer Boosts Stake with Share Purchase

CalciMedica's Chief Business Officer and Director, Eric W. Roberts, acquired 1,500 shares of common stock, signaling increased insider confidence.

Summary

• Eric W. Roberts, who serves as Chief Business Officer, Director, and a 10% owner of CalciMedica, Inc. (CALC), purchased 1,500 shares of the company's common stock.
• The transaction occurred on July 21, 2025, at a weighted average purchase price of $3.37 per share, with prices ranging from $3.33 to $3.43.
• The purchase was made indirectly through an FMTC Custodian Roth IRA FBO Eric W. Roberts.
• Following this transaction, Eric W. Roberts' total beneficial ownership in CalciMedica, Inc. stands at 1,012,410 shares, comprising 164,706 directly owned shares and 847,704 indirectly owned shares across various entities including Roth IRAs and Valence Investments SPVs.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a significant insider purchase by a key executive, indicating strong confidence in the company's future performance.

Positives

• A key insider, Eric W. Roberts, holding multiple significant roles (Chief Business Officer, Director, 10% Owner), increased his stake in the company, signaling strong confidence in CalciMedica's future prospects.
• The purchase was made at a price of $3.37 per share, indicating management's belief in the stock's value at or above this level.
• The transaction was conducted under a Rule 10b5-1 plan, which demonstrates a pre-planned, systematic approach to stock acquisition, often viewed positively as it mitigates concerns about opportunistic trading.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it primarily reports an insider transaction.

Industry Context

This insider purchase by a key executive at CalciMedica, a biopharmaceutical company, suggests internal confidence in the company's drug development pipeline or strategic direction, which is a common signal observed across the biotech industry.

Corporate Governance

Related Party Transactions

• The reported transaction is a direct purchase of company stock by an insider (Eric W. Roberts), who is a Director, Chief Business Officer, and 10% owner of CalciMedica, Inc.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of future stock performance and management's commitment to increasing shareholder value.
• Employees may perceive this as a sign of stability and confidence from leadership regarding the company's direction.

Key Dates

Recommendation

The purchase of shares by a high-ranking insider, particularly one with multiple roles including Director and Chief Business Officer, signals strong conviction in the company's prospects. Such insider buying often precedes positive developments or indicates a belief that the stock is undervalued, making it a compelling 'buy' signal for seasoned investors.

Keywords

CalciMedica, CALC, Insider Trading, Stock Purchase, Eric W. Roberts, Chief Business Officer, Director, 10% Owner, Beneficial Ownership, Form 4, SEC Filing, Rule 10b5-1